Doctors might need to up their patient load during opioid epidemic

There aren’t enough doctors to treat people with opioid addiction issues, according to a report by the RAND Corporation.

Only some doctors are qualified to prescribe certain drugs that help patients deal with withdrawal symptoms or overdose dangers from opioids. But they might not be treating as many patients as possible to make a dent in the nation’s opioid crisis.

NPR reported that the study looked at the 3,234 doctors that treated an average of 13 patients each with Suboxone (to help people dealing with withdrawal symptoms) between 2010 and 2013.

About 20 percent of those doctors were able to treat up to 75 new patients in that time. But another 22 percent treated less than four new patients. Maybe the key to getting more people medical help with substance abuse issues is getting qualified doctors to take on more patients?

According to NPR, certain governmental and healthcare organizations are working to make drugs such as Suboxone more easily available to patients who need them. For example, the Obama Administration has increased the number of patients a doctor can treat for addiction from 100 to 250. And some doctors are realizing they have to step in when their existing patients start to struggle with addiction.

Check out NPR to see what resources for physicians the study’s authors recommended, including education about treating patients with addiction issues. 

Caitlin Wilson,

Senior Writer

As a Senior Writer at TriMed Media Group, Caitlin covers breaking news across several facets of the healthcare industry for all of TriMed's brands.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.